Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: A clinical and economic perspective

Vatsal Patel, Michael Buckstein, Rodolfo Perini, Christine Hill-Kayser, Jakub Svoboda, John P. Plastaras

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

We studied the clinical benefits of radiological imaging, in the follow-up of patients after combined modality treatment for stage I/II classical supradiaphragmatic Hodgkin lymphoma (HL). Imaging data were collected for 78 adults treated during 1996-2008. Median follow-up was 4.6 years. Six of the nine relapses were detected clinically. On average, 31 imaging studies/patient were performed, with an estimated cost of $12 608/patient. Chest computed tomography (CT) scans accounted for 25%, abdominopelvic CT scans 41% and positron emission tomography (PET) or PET/CT scans 22% of this expense. Only one patient recurred infradiaphragmatically. The estimated radiation dose from imaging was 399 mSv and 229 mSv per patient, in relapse and non-relapse groups, respectively. CT scans contributed over 80% of the imaging radiation exposure. The routine use of CT scans in the surveillance of patients with HL after curative treatment adds to healthcare costs and total body radiation exposure with a low yield. History and physical examination remain effective tools for the follow-up of patients.

Original languageEnglish
Pages (from-to)2168-2176
Number of pages9
JournalLeukemia and Lymphoma
Volume54
Issue number10
DOIs
StatePublished - Oct 2013

Keywords

  • Clinical results
  • Lymphoma and Hodgkin disease
  • Prognostication
  • Radiation

Fingerprint

Dive into the research topics of 'Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: A clinical and economic perspective'. Together they form a unique fingerprint.

Cite this